Wegovy and SVT: what the evidence currently says

Step 1: understand how semaglutide affects heart rate

Before weighing any SVT-specific considerations, it helps to understand the baseline effect Wegovy has on the cardiovascular system. GLP-1 receptors are present in cardiac tissue, and semaglutide's activation of those receptors can produce a small increase in resting heart rate, typically in the region of two to four beats per minute in trial populations. This was recorded consistently across the STEP trial programme and is noted in the Wegovy prescribing information held on the electronic Medicines Compendium. For most people with healthy cardiac function, that increment is clinically unremarkable. For someone whose heart rhythm is already prone to running fast or breaking into episodes of SVT, even a modest upward nudge in baseline rate is worth flagging to a prescriber. The effect tends to be most noticeable in the weeks after a dose increase, so the titration schedule (which steps up slowly over several months) is part of how the risk is managed. It does not disappear entirely at maintenance dose, but it generally stabilises.

The NHS medicines information for semaglutide lists heart-related symptoms including palpitations and a fast or irregular heartbeat among side effects to discuss with a doctor. That list is not exclusive to people with SVT, but it signals why a thorough cardiac history matters before starting.

Step 2: think through your specific SVT picture

SVT is an umbrella term. Occasional episodes of AVNRT (the most common type, often felt as sudden rapid pounding that stops as abruptly as it started) managed without medication are a very different clinical situation from Wolff-Parkinson-White syndrome, atrial tachycardia requiring ablation, or frequent symptomatic episodes that have required emergency treatment. A prescriber reviewing a Wegovy consultation for someone with occasional, self-terminating SVT and no structural heart disease will approach the risk-benefit calculation differently from one seeing a patient with poorly controlled or frequent arrhythmia. There is no single answer that covers all presentations. What a prescriber will want to know includes: whether your SVT is diagnosed and monitored, what triggers episodes, whether you take antiarrhythmic medication (and whether any of those medicines interact with semaglutide's GI effects, vomiting and dehydration can themselves precipitate tachycardia), and whether a cardiologist is involved in your care. If they are, a brief note to them that you are starting a GLP-1 medicine is sensible practice, and our guide to using Wegovy alongside other conditions and treatments may help you think through what to raise in that conversation. You can read about some of the cardiovascular considerations for GLP-1 medicines on the NHS England weight-management injections guidance.

One practical habit worth building: before each new dose level, check your resting pulse on a phone fitness app or wrist monitor for three mornings running. It takes under a minute and gives you a baseline to share with your prescriber or cardiologist if you notice any change.

Step 3: consider the other side of the equation, obesity and SVT

This step is easy to overlook when you're focused on risk, but it matters clinically. Obesity is an independent risk factor for atrial arrhythmias and has documented associations with higher SVT burden. Excess adipose tissue, raised inflammatory markers, obstructive sleep apnoea and raised sympathetic nervous system activity all create conditions in which the heart is more irritable. Sustained weight reduction has been shown in multiple observational studies to reduce arrhythmia frequency and improve outcomes in people living with obesity-related cardiac conditions. That does not mean weight-loss treatment is automatically the right choice, it means the conversation with a prescriber is not purely about the risks of Wegovy. The potential benefit of meaningful weight loss on long-term arrhythmia burden is part of the picture too. For some people with SVT, the weight-loss benefit may genuinely outweigh the modest heart-rate effect; for others, the timing or the specific arrhythmia pattern may make it sensible to wait, or to have a cardiology review first. It is also worth knowing that semaglutide can interact with other aspects of your health in ways you might not expect, including changes to skin that some people notice during treatment and considerations around vitamin B12 levels, which can be affected by Wegovy over time. You can read more about how weight management interacts with broader health conditions on our weight-loss overview.

Step 4: what to expect from a clinical consultation at nume

At nume, every consultation is read by a GPhC-registered Independent Prescriber (not reviewed by software) on the same day it arrives. When you disclose SVT in your consultation, the prescriber considers the full clinical picture: the type of arrhythmia, any current medication, your BMI, and any other weight-related conditions. They may approve treatment, suggest you obtain a cardiology sign-off first, or advise that treatment is not suitable at this time. That is the correct process. Because SVT presentations vary so much, the answer you get will be specific to you. If you are also taking HRT, it is worth reading about how Wegovy and HRT interact, as this is something prescribers will factor into their assessment. If you have questions about how our clinical team approaches cardiac histories, our clinical lead's profile sets out the medical oversight behind every decision. For a broader picture of what Wegovy involves (mechanism, eligibility, results evidence) our Wegovy guide covers the full landscape. If cost is a factor in your thinking, the Wegovy price comparison page explains what the market looks like and what a legitimate private prescription typically includes. When you feel ready, check your eligibility with a free consultation, there is no commitment involved, and the prescriber's job is to give you an honest answer, not an automatic approval.